H.C. Wainwright started following Coherus Oncology and thinks it's a good buy, setting a target price of $7.00.

CHRS · Coherus Oncology, Inc.

The AI's read

This adds a favorable outside view of Coherus Oncology. A share target is an analyst’s estimate, not a promise. The story reports no new sales, profits, or product progress, so the support comes from the rating.